The Brain Tumor Panel 1 is a focused molecular testing panel designed to detect key genetic alterations associated with various brain tumors. Metropolis Healthcare uses advanced sequencing methods on the provided sample to identify mutations that influence tumor behavior, prognosis, and targeted therapy options. This test supports accurate diagnosis and personalized treatment planning for patients with suspected or confirmed brain tumors. It is especially useful in guiding oncologists toward precision-based clinical decisions
Price:
Rs. 20,670.00
Sample Type: Slide , Tissue
Fasting Not Required
Notes:G0336
Frequently Asked Questions (FAQ's):
What does the Brain Tumor Panel 1 include?
It includes analysis of essential genes commonly altered in brain tumors to help clarify diagnosis and guide treatment.
How does Metropolis Healthcare perform this test?
Metropolis Healthcare uses high-quality molecular techniques and sequencing platforms to detect critical genetic mutations in tumor samples.
Who should take this test?
Patients with confirmed or suspected brain tumors who require detailed molecular profiling for treatment planning should consider this test.
Why is genetic testing important for brain tumors?
It helps determine tumor subtype, predicts prognosis, and identifies potential targeted therapy options.
What type of sample is required?
A tumor tissue sample, usually obtained through biopsy or surgical resection, is typically needed for this panel.
How accurate are results from Metropolis Healthcare?
Metropolis Healthcare uses validated assays and strict quality protocols to ensure high-precision and clinically reliable results.
Can this test help in selecting targeted therapies?
Yes, the panel identifies mutations linked to therapies that may be more effective based on the tumor’s genetic profile.
How soon can I expect the report?
Metropolis Healthcare provides reports within the standard turnaround time for molecular tumor panels